Multiple Sclerosis Therapeutics; Depends On the Stage of the Disease and the Specific Symptoms the Person Has
There's currently no cure for multiple sclerosis (MS), but multiple sclerosis therapeutics, such as medicines and other treatments, can help control the condition and ease some symptoms. Treatment typically focuses on speeding recovery from attacks, slowing the progression of the disease, and managing MS symptoms. Some people have such mild symptoms that no treatment is necessary. There is no cure for MS (multiple sclerosis), but early, aggressive treatment at the earliest signs of the disease can prevent recurrent attacks.
Multiple
Sclerosis Therapeutics is a chronic disease that affects the central nervous
system, which is the brain, spinal cord, and optic nerves. MS is an autoimmune
disease, a potentially disabling disease of the brain and spinal cord (central
nervous system). The cause of multiple sclerosis is unknown. It's considered an
autoimmune disease in which the body's immune system attacks its own tissues. This
immune system malfunction destroys the fatty substance that coats and protects
nerve fibers in the brain and spinal cord (myelin).
Today,
first-line treatments for Multiple
Sclerosis Therapeutics include injectable immunomodulators - some of which have
been on the market for nearly 25 years, as well as teriflunomide and dimethyl
fumarate, which are more recent but have opened the way for oral treatments. The
U.S. Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) to treat
adult patients with relapsing forms of multiple sclerosis (MS) and primary
progressive multiple sclerosis (PPMS). This was the first drug approved by the
FDA for PPMS.
Moreover,
for primary-progressive MS, ocrelizumab (Ocrevus) is the only U.S. FDA-approved
disease-modifying therapy (DMT). If treatment is not started early, disability
can accumulate and patients may experience irreversible neurological damage. Early
recognition and accurate diagnosis of MS are crucial to delaying disease
progression and improving patients' outcomes.
Comments
Post a Comment